Biotech regulatory gaps
Absence of clear regulatory guidance from bodies like MHRA for genetically engineered (GE) phages and enzymes.
2 items
1 source
1 inquiry
Source spread
Where this theme appears
Biotech regulatory gaps has been flagged across 1 independent accountability source:
2 inquiry recs
This theme has been identified in one data source. As more data is added, cross-references may emerge.
Browse by source
Source-grouped records are useful for tracing where a concern came from. Large sections show the 50 strongest matches for that source; counts still show the full theme total.
Inquiry Recommendations (2)
COVID-M4.1 — Establish Pharmaceutical Expert Advisory Panel
Recommendation: The UK government should establish a standing pharmaceutical expert advisory panel, in consultation with the Department of Health and Social Care and the Department for Science, Innovation and Technology. The panel should include ministers, civil servants and representatives from industry …
Words of: UK government (Department of Health and Social Care), UK government response to the Covid-19 Inquiry Module 4 report (CP 1684), 16 October 2026
Gov response: The COVID-19 pandemic demonstrated the critical importance of expert advice to inform government decision-making and the value of drawing on expertise from across science, academia and the life sciences sector. The Scientific Advisory Group for …
Accepted in part
COVID-M5.4 — Emergency Healthcare Equipment Regulations
Recommendation: The UK government and devolved administrations should publish simplified regulations for emergency healthcare equipment that are aligned with and cover the range and severity of pandemic risks identified in the National Security Risk Assessment. The simplified regulations should: establish the …
Gov response: No formal government response published. The Northern Ireland Executive had not published a response to the Module 5 report of 14 July 2026 when the Executive Office's publications list was checked on 25 September 2026.
No response yet